Inside information: Orion upgrades full-year outlook for 2024 and provides preliminary information on financial performance for 2024 ORION...
Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2025 Annual General Meeting ORION CORPORATION STOCK...
79,345 Orion Corporation A shares converted into B shares ORION CORPORATIONSTOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE...
Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide ORION CORPORATION INVESTOR NEWS 7 JANUARY...
Orion and Marinus terminate agreement for ganaxolone in Europe ORION CORPORATION PRESS RELEASE 30 DECEMBER 2024 at 14.00 EET Orion and...
CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel ORION CORPORATION...
Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel ORION CORPORATION STOCK EXCHANGE...
Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics ORION...
Penalty payment to a member of Orion’s Board of Directors for delay in notifying managers’ transaction ORION CORPORATION STOCK EXCHANGE RELEASE –...
142,701 Orion Corporation A shares converted into B shares ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE...
Orion Research Foundation grants EUR 1,109,000 for research in 2025 Orion Research Foundation grants EUR 1,109,000 for research in 2025 Press...
Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies ORION CORPORATION INVESTOR NEWS 19 NOVEMBER 2024 at...
Orion Corporation: Managers’ transactions – Henrik Stenqvist ORION CORPORATION MANAGERS’ TRANSACTIONS 1 NOVEMBER 2024 at 9.45 EET Orion...
Orion Group Interim Report January–September 2024 ORION CORPORATION INTERIM REPORT 1–9/2024 29 OCTOBER 2024 at 12:00 EET Orion Group Interim...
Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule ORION CORPORATION STOCK EXCHANGE...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads